Chief Financial Officer Karsten Munk Knudsen guided 2025 sales growth of 13% to 21% at constant exchange rates, stating the outlook assumed a reduction in patients on compounded GLP-1 treatments in the second half of 2025
Both doctors warn against doing this
Embarking on a weight loss journey is a significant step towards better health and well-being
Miembro del Board Latinoamericano de Eli Lilly y Sanofi Aventis Miembro del board nacional de los laboratorios Novo Nordisk, Novartis, GlaxoSmithKline, Sanofi Aventis, Boheringer Ingelheim, Bristol Myers, Astra Zeneca Investigador principal de protocolos pertenecientes a Eli Lilly, Novo Nordisk, Novartis, GlaxoSmithKline, Takeda, PPDF, Pfizer, Merck Sharp Dome, Amgen, Roche, Minimed, Quintiles Conferencista de los laboratorios mencionados
Administration routes include intramuscular and subcutaneous injections